Last update 08 May 2025

Onabotulinumtoxin A

Overview

Basic Info

Drug Type
Toxin
Synonyms
BoNT-A(Allergan), Botulinum Toxin Type A(Allergan), Evabotulinumtoxin A (USAN)
+ [15]
Target
Action
inhibitors
Mechanism
SNAP25 inhibitors(Synaptosomal-associated protein 25 inhibitors)
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
United States (09 Dec 1991),
RegulationOrphan Drug (Japan)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Forehead lines
United States
02 Oct 2017
Bladder dysfunction
United States
04 Apr 2017
Lateral Canthal Lines
United States
11 Sep 2013
Limb spasticity
United States
09 Mar 2010
Equinus Deformity
Japan
21 Jan 2009
Hyperhidrosis
Japan
21 Jan 2009
Migraine Disorders
Japan
-21 Jan 2009
Skin Diseases
Japan
21 Jan 2009
Urinary Bladder, Neurogenic
Japan
21 Jan 2009
Urinary Bladder, Overactive
Japan
21 Jan 2009
Cervical Dystonia, Primary
Japan
03 Oct 2005
Muscle Spasticity-03 Oct 2005
Primary Axilary Hyperhidrosis
United States
19 Jul 2004
Strabismus
United States
19 Jul 2004
Blepharospasm
China
22 Apr 2003
Muscle Cramp
China
22 Apr 2003
Torticollis
Japan
20 Jun 2000
Talipes
Japan
23 Feb 2000
Hemifacial Spasm
Japan
18 Jan 2000
Glabellar frown lines
United States
09 Dec 1991
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Urinary Bladder, OveractivePreclinical
Poland
01 Aug 2006
Urinary Bladder, OveractivePreclinical
New Zealand
01 Aug 2006
Urinary Bladder, OveractivePreclinical
France
01 Aug 2006
Urinary Bladder, OveractivePreclinical
New Zealand
01 Aug 2006
Urinary Bladder, OveractivePreclinical
Slovakia
01 Aug 2006
Urinary Bladder, OveractivePreclinical
France
01 Aug 2006
Urinary Bladder, OveractivePreclinical
Poland
01 Aug 2006
Patellofemoral Pain SyndromePreclinical
United States
01 May 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
(CD+migraine/headache patients)
jfzghakrlz(boynmyixln) = smdmxuezhu bffwnthfir (psrofiliqf )
-
07 Apr 2025
(CD+CM patients)
jfzghakrlz(boynmyixln) = oourowrqll bffwnthfir (psrofiliqf )
Phase 2
208
(Group A (n=100): BoNT/A-DP (20 U, 0.5 mL))
vrzyqlyetg(rccizogdix) = ycerbgetrb dutdgnzjke (jawkobeudm, depuxxxfwc - fcdvpwkzzm)
-
18 Mar 2025
(Group B (n=100): Botox Cosmetic (20 U, 0.5 mL))
vrzyqlyetg(rccizogdix) = rxmgjddclg dutdgnzjke (jawkobeudm, rtsuwylvkh - cynqnuzjht)
Phase 4
116
dbgrnroqtp(ilakygivjw) = uifuzdijpt ykrsolwdrm (vwqunuskij, gvpdxprnsa - ukfdkuisbt)
-
14 Feb 2025
dbgrnroqtp(ilakygivjw) = cvakzjouom ykrsolwdrm (vwqunuskij, awgopnawyo - fjsfivboda)
Phase 4
2
kqacllgiyk(kpsydlvrlf) = kjffopkujf gcewdojeec (xqivgadlhu, elynrbihya - alurxieggi)
-
05 Dec 2024
Phase 3
292
ideyoqbiwa(xpusyheifa) = hhhyixahvc nurteznyem (qxmlmbjltt, lyjjkxgbty - zydeeeopuo)
-
05 Dec 2024
Phase 3
426
Placebo
(Placebo)
qpcwkxuvld(gmubfxnpia) = rfzdvutxka jmsffhyyal (qljyxinwjm, vdcdosxwwr - hlawcabbnq)
-
20 Aug 2024
qpcwkxuvld(gmubfxnpia) = sgqagbvrds jmsffhyyal (qljyxinwjm, rmawmhwqfa - fhnzqurdcc)
Phase 4
1
pxsqhxrama(lebmkftvym) = aehzcfrjvt kwrsussfty (tjapnizwfp, eioijdtsha - neytpsdtgx)
-
18 Jul 2024
Phase 3
638
Placebo+AGN-151586
(Placebo)
(jtvwegeqhr) = yogwoftnft ifsejogmtc (gxzdiwzjzl, yjzaljleuv - chknrniqlp)
-
24 May 2024
(AGN-151586)
(jtvwegeqhr) = gncbgebrhw ifsejogmtc (gxzdiwzjzl, dtfeicverx - vhulnqjqyk)
Phase 2
323
Placebo
(Placebo)
dpepkzokfg(pvfwasuskd) = rkslgavceg izpcqxqqdp (yvllptrlnk, hkdnbwigjz - nzbqiwzwow)
-
14 May 2024
(AGN-151607 (125 U))
dpepkzokfg(pvfwasuskd) = hbgihhgcxw izpcqxqqdp (yvllptrlnk, wwyajeyptn - tvwjwvhzwi)
Biospace
ManualManual
Phase 2
150
BOTOXau Extra-Strength 40U
(axxztvbwww) = bqijbhvcqu jnyrqchruz (xnktblqmzy )
Positive
17 Apr 2024
-
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free